GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have been given a consensus rating of “Moderate Buy” by the fifteen research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, nine have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $9.36.

A number of analysts have weighed in on the company. TD Cowen upped their target price on GoodRx from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, May 16th. Barclays upped their price objective on GoodRx from $9.00 to $10.00 and gave the stock an “overweight” rating in a research note on Monday, May 20th. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 target price on shares of GoodRx in a research note on Friday, August 16th. Raymond James upgraded shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 target price for the company in a report on Friday, August 9th. Finally, Citigroup lowered their price target on shares of GoodRx from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 9th.

GoodRx Stock Performance

GDRX stock opened at $7.72 on Friday. GoodRx has a 1-year low of $4.14 and a 1-year high of $9.26. The business has a 50-day moving average price of $8.04 and a 200 day moving average price of $7.59. The company has a market capitalization of $2.90 billion, a P/E ratio of -772.00, a PEG ratio of 3.65 and a beta of 1.38. The company has a debt-to-equity ratio of 0.96, a current ratio of 7.32 and a quick ratio of 7.32.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). GoodRx had a negative net margin of 7.57% and a positive return on equity of 3.63%. The business had revenue of $200.60 million during the quarter, compared to the consensus estimate of $200.47 million. During the same quarter in the prior year, the firm posted $0.02 EPS. The company’s revenue for the quarter was up 5.7% compared to the same quarter last year. As a group, equities research analysts forecast that GoodRx will post 0.15 EPS for the current fiscal year.

Insider Buying and Selling at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total value of $83,921.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 4.17% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On GoodRx

Large investors have recently bought and sold shares of the company. Rubric Capital Management LP acquired a new stake in GoodRx during the 4th quarter valued at approximately $39,348,000. American Century Companies Inc. purchased a new position in shares of GoodRx during the second quarter worth $18,183,000. Millennium Management LLC lifted its position in GoodRx by 36.5% during the second quarter. Millennium Management LLC now owns 4,121,939 shares of the company’s stock valued at $32,151,000 after purchasing an additional 1,102,758 shares during the period. Picton Mahoney Asset Management purchased a new stake in GoodRx in the first quarter valued at $3,467,000. Finally, Rip Road Capital Partners LP grew its position in GoodRx by 25.8% during the 4th quarter. Rip Road Capital Partners LP now owns 1,763,277 shares of the company’s stock worth $11,814,000 after purchasing an additional 361,294 shares during the period. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.